The Evolving Treatment Landscape for HR+/HER2- Breast Cancer: Updates and Considerations for Managed Care

The Evolving Treatment Landscape for HR+/HER2- Breast Cancer: Updates and Considerations for Managed Care is organized by Pharmacy Times Continuing Education (PTCE).,Release date: October 21, 2022,Expiration date: October 21, 2023,Description:,Despite recent improvements in the treatment and management of breast cancer, the prognosis for patients is dependent on the stage and type of cancer. Hormone receptor-positive (HR+) / human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for 70% of all cases; while it is generally diagnosed in the early stage with favorable cure rates, the median overall survival for those diagnosed with advanced breast cancer is just 2 to 3 years. More targeted treatments, such as cyclin-dependent kinase (CDK) 4/6 inhibitors, are being developed to combat advanced HR+/HER2- disease. This program will focus on recent clinical trial updates on the long-term efficacy and safety of CDK4/6 inhibitors and endocrine therapies in specific patient populations with advanced HR+/HER2- breast cancer. As quality of life is a central factor in the choice of treatments, the impact of adverse effect profiles of the CDK4/6 inhibitors is important for treatment selection and management of patients with advanced breast cancer. Additional considerations for managed care pharmacists on the multidisciplinary oncology care team to integrate treatment recommendations and proactively manage drug therapy while mitigating costs for patients and the healthcare system will be discussed.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Break down the pathogenesis of breast cancer, the guideline-recommended approach to care, and the treatment goals for patients with hormone receptor-positive (HR+) / human epidermal growth factor receptor 2-negative (HER2-) advanced and metastatic breast cancer.,• Analyze the recent clinical data for the FDA-approved cyclin-dependent kinase (CDK) 4/6 inhibitors and novel endocrine therapies in the treatment of HR+/HER2- breast cancer.,• Identify strategies to integrate recent clinical updates into treatment protocols for the management of HR+/HER2- metastatic breast cancer to optimize outcomes and healthcare resource utilization.